M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
* Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx1
* This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care
* These data...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search